Recently, the VetStem sales and marketing team attended two veterinary shows. One team was in Lexington, KY at the International Society of Equine Locomotor Pathology (ISELP) Proximal Forelimb and Neck Connection module while the other team was in Nashville, TN at the Fetch Nashville conference. At both shows, we were excited to announce that our platelet-rich plasma (PRP) products, PrecisePRP™ Canine and PrecisePRP™ Equine, have completed FDA review.

PrecisePRP™ is intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration and is unlike any PRP mechanical kit currently on the market. PrecisePRP™ is a freeze-dried, donor-derived (allogeneic) platelet-rich plasma product. Unlike mechanical PRP kits, PrecisePRP™ does not require a blood draw or centrifugation, nor refrigeration, making it a truly off-the-shelf product that is easy and convenient.

Perhaps more important is the uniformity and consistency that PrecisePRP™ provides with its unique patent pending manufacturing process. Each vial of PrecisePRP™ contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter. Additionally, each lot is quality tested before release.

According to the FDA, PrecisePRP™ Canine and PrecisePRP™ Equine are the only FDA-reviewed PRP products for dogs and horses available to veterinarians. Both products underwent thorough evaluations by the Center for Veterinary Medicine that resulted in formal risk reviews. According to the FDA, “the developer of PrecisePRP properly identified and appropriately mitigated the potential risks associated with the product, and the FDA has no additional safety concerns.”

Understandably, veterinarians are very excited about these new products. PrecisePRP™ is not only easy, it’s also consistent, allowing veterinarians to know that the PRP they are injecting has been quality tested for sterility, platelet count, and potency. In providing a more consistent product and what is believed to be a therapeutic dose of PRP, the goal is to achieve more favorable outcomes. To learn more about PrecisePRP™, visit our website.

Platelet-rich plasma has been used in veterinary medicine for over 20 years. It is commonly used to treat musculoskeletal diseases and injuries such as osteoarthritis and injured tendons and ligaments. It has also been used topically for wounds and corneal ulcers as well as several other indications. The principle of PRP therapy is to accelerate lagging internal healing processes by amplifying the biological signals that would naturally occur when platelets aggregate at a site of injury. By concentrating platelets and releasing more of those growth factors than would naturally occur, the intended effect is to attract stem cells and other healing cells to stimulate local tissue repair processes.